Value of Adjuvant Therapy With Bacille Calmette Guerin (BCG) or Dimethl Triazeno Imidazole Carboximide (DTIC) in the Control of Minimal Residual Disease in Stage II Melanoma

This publication has 15 references indexed in Scilit:

• DIAGNOSIS, PROGNOSIS, AND TREATMENT OF MELANOMA
  The Lancet, 1977
• Combined immunotherapy in malignant melanoma: Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin
  Cellular Immunology, 1976
• Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant Melanoma
  New England Journal of Medicine, 1976
• The diagnostic value of the67gallium-szintigraphy in malignant melanoma
  Langenbecks Archives Of Surgery, 1975
• RESULTS OF ADMINISTERING B.C.G. TO PATIENTS WITH MELANOMA
  The Lancet, 1974
• Chemoimmunotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guérin
  New England Journal of Medicine, 1974
• ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA
  The Lancet, 1973
• Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared
  Annals of Internal Medicine, 1972
• Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma
  Annals of Surgery, 1970
• The classification of melanoma and its relationship with prognosis
  Pathology, 1970